Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Crosses Into Black for Q3

NEW YORK, Nov. 13 (GenomeWeb News) -Lynx Therapeutics today crossed into the black, reporting net income of $1.8 million for the third quarter of 2003.

 

"Our operating performance in the third quarter of 2003 reflects higher genomics revenues and continued aggressive management of our expenses," Kevin Corcoran, Lynx's President, said in a statement.

 

The Hayward, Calif., company's revenues came to $8.3 million for the third quarter, up from $4.8 million for the third quarter of last year.

 

R&D expenses decreased to $3.0 million, compared to $4.3 million for the same period last year.

As of Sept. 30, Lynx had $6.4 million in cash and cash equivalents, including restricted cash, compared to $11.7 million for the same period last year.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.